Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) EBITDA: 2022-2025

Historic EBITDA for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to -$52.4 million.

  • Abivax's EBITDA fell 38.85% to -$52.4 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$139.7 million, marking a year-over-year decrease of 62.14%. This contributed to the annual value of -$184.8 million for FY2024, which is 34.88% down from last year.
  • Abivax's EBITDA amounted to -$52.4 million in Q2 2025, which was down 6.06% from -$49.4 million recorded in Q1 2025.
  • Abivax's 5-year EBITDA high stood at -$66.11 for Q4 2022, and its period low was -$52.4 million during Q2 2025.
  • Moreover, its 3-year median value for EBITDA was -$43.1 million (2024), whereas its average is -$31.3 million.
  • Data for Abivax's EBITDA shows a maximum YoY slumped of 107.34% (in 2023) over the last 5 years.
  • Quarterly analysis of 4 years shows Abivax's EBITDA stood at -$66.11 in 2022, then crashed by 107.34% to -$137.07 in 2023, then crashed by 34.79% to -$184.76 in 2024, then crashed by 38.85% to -$52.4 million in 2025.
  • Its last three reported values are -$52.4 million in Q2 2025, -$49.4 million for Q1 2025, and -$184.76 during Q4 2024.